ZA202211465B - Tetrahydroisoquinoline compounds as nrf2 activators - Google Patents

Tetrahydroisoquinoline compounds as nrf2 activators

Info

Publication number
ZA202211465B
ZA202211465B ZA2022/11465A ZA202211465A ZA202211465B ZA 202211465 B ZA202211465 B ZA 202211465B ZA 2022/11465 A ZA2022/11465 A ZA 2022/11465A ZA 202211465 A ZA202211465 A ZA 202211465A ZA 202211465 B ZA202211465 B ZA 202211465B
Authority
ZA
South Africa
Prior art keywords
compounds
nrf2 activators
tetrahydroisoquinoline compounds
nrf2
activators
Prior art date
Application number
ZA2022/11465A
Other languages
English (en)
Inventor
Cathy Louise Lucas
Nicholas Charles Ray
Eileen Mary Seward
George Hynd
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of ZA202211465B publication Critical patent/ZA202211465B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2022/11465A 2020-04-22 2022-10-19 Tetrahydroisoquinoline compounds as nrf2 activators ZA202211465B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005863.2A GB202005863D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds
PCT/GB2021/050973 WO2021214470A1 (en) 2020-04-22 2021-04-22 Tetrahydroisoquinoline compounds as nrf2 activators

Publications (1)

Publication Number Publication Date
ZA202211465B true ZA202211465B (en) 2025-06-25

Family

ID=70860156

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/11465A ZA202211465B (en) 2020-04-22 2022-10-19 Tetrahydroisoquinoline compounds as nrf2 activators

Country Status (16)

Country Link
US (1) US20230167084A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139294B1 (cg-RX-API-DMAC7.html)
JP (1) JP7679400B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004720A (cg-RX-API-DMAC7.html)
CN (1) CN115667243B (cg-RX-API-DMAC7.html)
AR (1) AR121912A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021259366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174361A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032247T3 (cg-RX-API-DMAC7.html)
GB (1) GB202005863D0 (cg-RX-API-DMAC7.html)
IL (1) IL297434A (cg-RX-API-DMAC7.html)
MX (1) MX2022013398A (cg-RX-API-DMAC7.html)
PH (1) PH12022552775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214470A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211465B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207469A (en) * 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds
CR20240325A (es) * 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
KR20180017038A (ko) * 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
MY207469A (en) 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds

Also Published As

Publication number Publication date
AR121912A1 (es) 2022-07-20
JP2023524206A (ja) 2023-06-09
EP4139294B1 (en) 2025-04-09
EP4139294A1 (en) 2023-03-01
JP7679400B2 (ja) 2025-05-19
CN115667243A (zh) 2023-01-31
KR20230004720A (ko) 2023-01-06
CA3174361A1 (en) 2021-10-28
MX2022013398A (es) 2022-12-13
US20230167084A1 (en) 2023-06-01
AU2021259366A1 (en) 2022-11-10
GB202005863D0 (en) 2020-06-03
WO2021214470A1 (en) 2021-10-28
PH12022552775A1 (en) 2024-03-25
BR112022021244A2 (pt) 2022-12-06
CN115667243B (zh) 2025-01-07
IL297434A (en) 2022-12-01
ES3032247T3 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
PH12021550872A1 (en) Therapeutic compounds
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
MY209609A (en) Immunomodulators, compositions and methods thereof
PH12022553019A1 (en) Il-17a modulators
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2025009223A (es) Agentes de union a clec9a y su uso
PH12017501921A1 (en) Novel compounds
PH12022500021A1 (en) Il-17a modulators
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12022552775A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
EP4364805A3 (en) Novel pyridazines
MY201535A (en) Therapeutic compounds
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MY202884A (en) Compounds useful in hiv therapy
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity
PH12021550903A1 (en) Novel pyridazines
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2025006619A (es) Compuestos terapeuticos
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain